Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trial

T. Gaziano, JM. Castellano, A. Dymond, A. Looby, S. Mealing, R. Owen, S. Pocock, JR. González-Juanatey, A. Cordero, A. Fernández-Ortiz, A. Linhart, F. Schiele, W. Doehner, LO. Fernández, V. Fuster

. 2025 ; 55 (-) : 101348. [pub] 20250627

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25020681

BACKGROUND: The SECURE trial (NCT02596126) demonstrated the efficacy of the cardiovascular polypill ("CV-Polypill"-acetyl salicylic acid, atorvastatin and ramipril) in reducing the risk of recurrent major cardiovascular events compared with standard care when initiated within six months of a myocardial infarction. This analysis aimed to estimate the cost-effectiveness of the CV-Polypill from the Spanish healthcare perspective using SECURE trial data. METHODS: A decision analytic Markov modelling approach was conducted to compare the CV-Polypill with standard care over a lifetime time horizon. Six parametric distributions were fitted to SECURE trial data on time to reinfarction, stroke or death (cardiovascular or non-cardiovascular). Cost and utility data were sourced from literature. Respective model outputs were discounted at 3%. The model captured direct medical costs associated with treatment acquisition and acute/ongoing cardiovascular events. Probabilistic sensitivity analyses (PSA) and scenario analyses were conducted. FINDINGS: The CV-Polypill is dominant (improves health outcomes and reduces costs) in 84·8% of PSA iterations (848/1000 iterations), and cost effective in 89·3% of PSA iterations (893/1000 iterations) at a €30,000 threshold. Secondary prevention with the CV-Polypill reduces the recurrence of cardiovascular events and costs over the time horizon, from the Spanish healthcare perspective. A range of scenario analyses were conducted, demonstrating the robustness of the results when different inputs and assumptions were varied. INTERPRETATION: The CV-Polypill is a dominant strategy in secondary cardiovascular prevention, compared with standard care, from the Spanish healthcare perspective. The CV-Polypill should be considered as a secondary prevention for Spanish patients, like those enrolled in SECURE, at hospital discharge. FUNDING: By Ferrer International.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25020681
003      
CZ-PrNML
005      
20251014150354.0
007      
ta
008      
251007e20250627enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.lanepe.2025.101348 $2 doi
035    __
$a (PubMed)40678039
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gaziano, Thomas $u Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
245    10
$a Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trial / $c T. Gaziano, JM. Castellano, A. Dymond, A. Looby, S. Mealing, R. Owen, S. Pocock, JR. González-Juanatey, A. Cordero, A. Fernández-Ortiz, A. Linhart, F. Schiele, W. Doehner, LO. Fernández, V. Fuster
520    9_
$a BACKGROUND: The SECURE trial (NCT02596126) demonstrated the efficacy of the cardiovascular polypill ("CV-Polypill"-acetyl salicylic acid, atorvastatin and ramipril) in reducing the risk of recurrent major cardiovascular events compared with standard care when initiated within six months of a myocardial infarction. This analysis aimed to estimate the cost-effectiveness of the CV-Polypill from the Spanish healthcare perspective using SECURE trial data. METHODS: A decision analytic Markov modelling approach was conducted to compare the CV-Polypill with standard care over a lifetime time horizon. Six parametric distributions were fitted to SECURE trial data on time to reinfarction, stroke or death (cardiovascular or non-cardiovascular). Cost and utility data were sourced from literature. Respective model outputs were discounted at 3%. The model captured direct medical costs associated with treatment acquisition and acute/ongoing cardiovascular events. Probabilistic sensitivity analyses (PSA) and scenario analyses were conducted. FINDINGS: The CV-Polypill is dominant (improves health outcomes and reduces costs) in 84·8% of PSA iterations (848/1000 iterations), and cost effective in 89·3% of PSA iterations (893/1000 iterations) at a €30,000 threshold. Secondary prevention with the CV-Polypill reduces the recurrence of cardiovascular events and costs over the time horizon, from the Spanish healthcare perspective. A range of scenario analyses were conducted, demonstrating the robustness of the results when different inputs and assumptions were varied. INTERPRETATION: The CV-Polypill is a dominant strategy in secondary cardiovascular prevention, compared with standard care, from the Spanish healthcare perspective. The CV-Polypill should be considered as a secondary prevention for Spanish patients, like those enrolled in SECURE, at hospital discharge. FUNDING: By Ferrer International.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Castellano, José María $u Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
700    1_
$a Dymond, Amy $u York Health Economics Consortium (YHEC), York, United Kingdom
700    1_
$a Looby, Alissa $u York Health Economics Consortium (YHEC), York, United Kingdom
700    1_
$a Mealing, Stuart $u York Health Economics Consortium (YHEC), York, United Kingdom
700    1_
$a Owen, Ruth $u Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain $u London School of Hygiene and Tropical Medicine, London, United Kingdom
700    1_
$a Pocock, Stuart $u Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain $u London School of Hygiene and Tropical Medicine, London, United Kingdom
700    1_
$a González-Juanatey, José Ramón $u Hospital Clínico Universitario de Santiago de Compostela, IDIS, CIBERCV, Santiago de Compostela, Spain
700    1_
$a Cordero, Alberto $u Cardiology Department, Hospital Universitario de San Juan, Alicante, Spain
700    1_
$a Fernández-Ortiz, Antonio $u Hospital Clinico San Carlos, Idissc, Universidad Complutense, Madrid, Spain
700    1_
$a Linhart, Aleš $u Všeobecná Fakultní Nemocnice v Praze, Prague, Czech Republic
700    1_
$a Schiele, François $u Centre Hospitalier Régional Universitaire de Besançon - Hôpital Jean Minjoz, University of Franche Comte SINERGIES, Besancon, France
700    1_
$a Doehner, Wolfram $u Berlin Institute of Health Center for Regenerative Therapies, Charité - Universitätsmedizin Berlin, Berlin, Germany $u Deutsches Herzzentrum der Charité, Department Cardiology (Virchow Klinikum), Charité - Universitätsmedizin Berlin, - German Centre for Cardiovascular Research Partner Site Berlin, Germany $u Center for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Fernández, Luisa Ojeda $u Laboratory of Cardiovascular Prevention, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
700    1_
$a Fuster, Valentín $u Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain $u Mount Sinai Fuster Heart Hospital, The Mount Sinai Hospital, New York, USA
773    0_
$w MED00208007 $t The Lancet regional health. Europe $x 2666-7762 $g Roč. 55 (20250627), s. 101348
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40678039 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20251007 $b ABA008
991    __
$a 20251014150400 $b ABA008
999    __
$a ok $b bmc $g 2410887 $s 1258837
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 55 $c - $d 101348 $e 20250627 $i 2666-7762 $m The Lancet regional health. Europe $n Lancet Reg Health Eur $x MED00208007
LZP    __
$a Pubmed-20251007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace